NCT05603130 is a clinical trial of routinely collected clinical information in COVID-19 Disease, sponsored by Les Laboratoires des Médicaments Stériles.

Who is sponsoring NCT05603130?

NCT05603130 is sponsored by Les Laboratoires des Médicaments Stériles.

What drugs are being tested in NCT05603130?

Interventions in NCT05603130: routinely collected clinical information.

What condition does NCT05603130 study?

NCT05603130 studies COVID-19 Disease.

Is NCT05603130 still recruiting?

NCT05603130 is currently completed. Last updated 2 November 2022.

Last reviewed 2022-11-02 · How we verify

NCT05603130

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiologic Register on Diabetes and COVID-19 in Tunisia

Completed Last updated 2 November 2022

What this trial tests

trial testing routinely collected clinical information in COVID-19 Disease in 811 participants. Completed in 17 October 2022.

Timeline

23 March 2022

Primary endpoint
30 June 2022

17 October 2022

Quick facts

Lead sponsor	Les Laboratoires des Médicaments Stériles
Status	Completed
Study type	OBSERVATIONAL
Enrollment	811
Start date	23 March 2022
Primary completion	30 June 2022
Estimated completion	17 October 2022
Sites	1 location across Tunisia

Drugs / interventions tested

routinely collected clinical information

Conditions studied

COVID-19 Disease — all drugs for COVID-19 Disease →

Sponsor

Les Laboratoires des Médicaments Stériles — full company profile →

Who can join

18 and older, any sex, with COVID-19 Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CoviDTUN is a multicenter observatory set up by a steering committee to determine the presentation and evolution of diabetes in COVID-19 and study its pathogenesis. The observatory comprises a dataset consisting of routinely collected clinical information anonymously to be entered by the investigator as a participating clinician/researcher. The study will be an opportunity to understand the relationship between COVID-19 and diabetes, to enrich Tunisian data on diabetic and de novo diabetic patients who have contracted COVID-19 and to evaluate the prognostic severity factors for better management of these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Les Laboratoires des Médicaments Stériles trials

Trials by the same sponsor.

NCT06999551 — Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients. · Phase 4 · not yet recruiting
NCT06862726 — Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation · Phase 4 · enrolling by invitation
NCT06503965 — Tunisian Registry of Trans Catheter Aortic Valve Implantation · recruiting
NCT04607239 — The Impact of Telemonitoring in the Management of Hypertension · NA · unknown
NCT04193358 — Impact of A Nutritional Supplements' Combination (FERTILIS) on Male Infertility · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05603130 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Les Laboratoires des Médicaments Stériles
Last refreshed: 2 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05603130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing